MGMT and neoplasm: It can therefore be concluded that promoter hypermethylation of MGMT, CDH1, RAR-β and SYK genes, and loss of expression of RAR-β and RAR-β2 in ovarian cancers (GCTs) is relatively common and this may also be useful as a tumour marker for early diagnosis and subsequent disease monitoring.